Patient safety

Drugs often approved for wider use than tested, says Swiss study

Drug approval in Switzerland much slower than in Europe

This content was published on Jul 20, 2025 A study by the University of Zurich, ETH Zurich and Yale and Harvard universities found that many medicines are approved for groups not tested in trials.

New treatments

Swiss inaction threatens global antibiotic development push

This content was published on Jul 8, 2025 Switzerland risks stalling global antibiotic innovation amid rising resistance.

Patient safety

Global concern over measles is rising. Should Switzerland worry?

This content was published on May 30, 2025 Measles is making a global comeback. In Switzerland, a crisis is unlikely – but authorities warn a strong vaccination rate remains crucial.

Patient safety

WHO members approve global climate plan

This content was published on May 28, 2025 WHO member states have approved a global plan to strengthen initiatives that limit the effects of industry on health.

Patient safety

Lost stem cells: the scandal of a Swiss cord blood bank

This content was published on Mar 21, 2025 Imagine placing all your hopes on your baby’s stem cells to save their life or yours, only to fear seeing that hope vanish along with your child’s cells.

What do you think about advanced health technologies such as freezing cord blood?

Do you have any experience with such solutions? Do you think more or less regulation is needed and why?

Join the discussion

Feb 11, 2025

15 Likes

8 Comments

View the discussion

There are thousands of videos about weight-loss drugs on social media that can be seen from anywhere in the world.

Medicine access

Swiss regulator and media clash over weight-loss drugs

This content was published on Jan 21, 2025 Swissmedic has taken legal action against media for alleged unauthorised advertising of weight-loss drugs. Swiss media say this is censorship.

Swiss AI

AI regulations must strike a balance between innovation and safety

This content was published on Dec 19, 2024 What risks do citizens face in countries where artificial intelligence (AI) is not regulated, like Switzerland?

Medicines regulators weigh hope and hype with new Alzheimer’s drugs

This content was published on Sep 30, 2024 Swissmedic is expected to decide on the approval of the first new drug for Alzheimer’s disease in two decades. The decision won’t be easy.

Battling the rising tide of fake medicine

This content was published on Jul 4, 2024 Sales of counterfeit drugs are booming around the world, putting thousands of lives at risk. Why is it so hard to stem the tide of fake medicine?

Patient safety

Popular Stories

Most Discussed

Patient safety

More

Drugs often approved for wider use than tested, says Swiss study

More

Swiss inaction threatens global antibiotic development push

More

Global concern over measles is rising. Should Switzerland worry?

More

WHO members approve global climate plan

More

Lost stem cells: the scandal of a Swiss cord blood bank

More

What do you think about advanced health technologies such as freezing cord blood?

More

Swiss regulator and media clash over weight-loss drugs

More

AI regulations must strike a balance between innovation and safety

More

Medicines regulators weigh hope and hype with new Alzheimer’s drugs

More

Battling the rising tide of fake medicine

Popular Stories

Most Discussed